HEPA
Hepion Pharmaceuticals
HEPA
HEPA
Delisted
HEPA was delisted on the 12th of May, 2025.
16 hedge funds and large institutions have $5.43M invested in Hepion Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
16
Holders Change
-10
Holders Change %
-38.46%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
4
Closed
12
Calls
$46K
Puts
–
Net Calls
+$46K
Net Calls Change
-$98K
Top Buyers
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$1.63M |
| 2 |
Morgan Stanley
New York
|
+$199K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$72.6K |
| 4 |
BlackRock
New York
|
+$58.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$22K |
Top Sellers
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$122K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$103K |
| 3 |
Bank of New York Mellon
New York
|
-$68.9K |
| 4 |
ML
McAdam LLC
Philadelphia,
Pennsylvania
|
-$48.3K |
| 5 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$47.5K |
